{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:40:25Z","timestamp":1784022025689,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,18]]},"DOI":"10.7759\/cureus.31648","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T17:11:14Z","timestamp":1668791474000},"source":"Crossref","is-referenced-by-count":9,"title":["Gastrointestinal Microbiota and Breast Cancer Chemotherapy Interactions: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Denise","family":"Csendes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Dheeraj","family":"Gutlapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthana","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran Maee","family":"Swarnakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohana Priya","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabab","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneeque","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshi  M","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics","volume":"72","author":"Siegel RL","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2022, 72:7-33. 10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks AG","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019, 321:288-300. 10.1001\/jama.2018.19323","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast\u00a0cancer (ABC 5)","volume":"31","author":"Cardoso F","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, et al.. 5th ESO-ESMO international consensus guidelines for advanced breast\u00a0cancer (ABC 5). Ann Oncol. 2020, 31:1623-49. 10.1016\/j.annonc.2020.09.010","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE- 355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes J","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, et al.. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE- 355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020, 396:1817-28. 10.1016\/s0140-6736(20)32531-9","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid P","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al.. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020, 382:810-21. 10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi S","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al.. Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022, 387:9-20. 10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv147","article-title":"Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study","volume":"107","author":"Goedert JJ","year":"2015","unstructured":"Goedert JJ, Jones G, Hua X, et al.. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015, 107:djv147. 10.1093\/jnci\/djv147","journal-title":"J Natl Cancer Inst"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17472","article-title":"Role of gut microbiota dysbiosis in breast cancer and novel approaches in prevention, diagnosis, and treatment","volume":"13","author":"Ruo SW","year":"2021","unstructured":"Ruo SW, Alkayyali T, Win M, et al.. Role of gut microbiota dysbiosis in breast cancer and novel approaches in prevention, diagnosis, and treatment. Cureus. 2021, 13:e17472. 10.7759\/cureus.17472","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/srep30751","article-title":"The microbiome of aseptically collected human breast tissue in benign and malignant disease","volume":"6","author":"Hieken TJ","year":"2016","unstructured":"Hieken TJ, Chen J, Hoskin TL, et al.. The microbiome of aseptically collected human breast tissue in benign and malignant disease. Sci Rep. 2016, 6:30751. 10.1038\/srep30751","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01235-16","article-title":"The microbiota of breast tissue and its association with breast cancer","volume":"82","author":"Urbaniak C","year":"2016","unstructured":"Urbaniak C, Gloor GB, Brackstone M, Scott L, Tangney M, Reid G. The microbiota of breast tissue and its association with breast cancer. Appl Environ Microbiol. 2016, 82:5039-48. 10.1128\/AEM.01235-16","journal-title":"Appl Environ Microbiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.03.040","article-title":"Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans","volume":"169","author":"Scott TA","year":"2017","unstructured":"Scott TA, Quintaneiro LM, Norvaisas P, et al.. Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans. Cell. 2017, 169:442-56.e18. 10.1016\/j.cell.2017.03.040","journal-title":"Cell"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2021.04.014","article-title":"Manipulations of the gut microbiome alter chemotherapy-induced inflammation and behavioral side effects in female mice","volume":"95","author":"Grant CV","year":"2021","unstructured":"Grant CV, Loman BR, Bailey MT, Pyter LM. Manipulations of the gut microbiome alter chemotherapy-induced inflammation and behavioral side effects in female mice. Brain Behav Immun. 2021, 95:401-12. 10.1016\/j.bbi.2021.04.014","journal-title":"Brain Behav Immun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3284","article-title":"Gene signature-based prediction of triple-negative breast cancer patient response to neoadjuvant chemotherapy","volume":"9","author":"Zhao Y","year":"2020","unstructured":"Zhao Y, Schaafsma E, Cheng C. Gene signature-based prediction of triple-negative breast cancer patient response to neoadjuvant chemotherapy. Cancer Med. 2020, 9:6281-95. 10.1002\/cam4.3284","journal-title":"Cancer Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan V","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, et al.. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018, 359:97-103. 10.1126\/science.aan4236","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.044","article-title":"Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients","volume":"78","author":"Derosa L","year":"2020","unstructured":"Derosa L, Routy B, Fidelle M, et al.. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol. 2020, 78:195-206. 10.1016\/j.eururo.2020.04.044","journal-title":"Eur Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy B","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, et al.. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018, 359:91-7. 10.1126\/science.aan3706","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2021.96","article-title":"Emerging actionable targets to treat therapy-resistant colorectal cancers","volume":"5","author":"Grassilli E","year":"2022","unstructured":"Grassilli E, Cerrito MG. Emerging actionable targets to treat therapy-resistant colorectal cancers. Cancer Drug Resist. 2022, 5:36-63. 10.20517\/cdr.2021.96","journal-title":"Cancer Drug Resist"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.11.006","article-title":"Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial","volume":"161","author":"Juan Z","year":"2022","unstructured":"Juan Z, Chen J, Ding B, et al.. Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial. Eur J Cancer. 2022, 161:10-22. 10.1016\/j.ejca.2021.11.006","journal-title":"Eur J Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.762929","article-title":"Probiotics for the treatment of docetaxel-related weight gain of breast cancer patients-a single-center, randomized, double-blind, and placebo-controlled trial","volume":"8","author":"Juan Z","year":"2021","unstructured":"Juan Z, Qing Z, Yongping L, et al.. Probiotics for the treatment of docetaxel-related weight gain of breast cancer patients-a single-center, randomized, double-blind, and placebo-controlled trial. Front Nutr. 2021, 8:762929. 10.3389\/fnut.2021.762929","journal-title":"Front Nutr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00902","article-title":"Gut microbiota profiling in patients with HER2-negative metastatic breast cancer receiving metronomic chemotherapy of capecitabine compared to those under conventional dosage","volume":"10","author":"Guan X","year":"2020","unstructured":"Guan X, Ma F, Sun X, et al.. Gut microbiota profiling in patients with HER2-negative metastatic breast cancer receiving metronomic chemotherapy of capecitabine compared to those under conventional dosage. Front Oncol. 2020, 10:902. 10.3389\/fonc.2020.00902","journal-title":"Front Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26082266","article-title":"Fecal metabolic profiling of breast cancer patients during neoadjuvant chemotherapy reveals potential biomarkers","volume":"26","author":"Zidi O","year":"2021","unstructured":"Zidi O, Souai N, Raies H, et al.. Fecal metabolic profiling of breast cancer patients during neoadjuvant chemotherapy reveals potential biomarkers. Molecules. 2021, 26:2266. 10.3390\/molecules26082266","journal-title":"Molecules"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.865121","article-title":"Metagenomic analyses reveal distinct gut microbiota signature for predicting the neoadjuvant chemotherapy responsiveness in breast cancer patients","volume":"12","author":"Li Y","year":"2022","unstructured":"Li Y, Dong B, Wu W, et al.. Metagenomic analyses reveal distinct gut microbiota signature for predicting the neoadjuvant chemotherapy responsiveness in breast cancer patients. Front Oncol. 2022, 12:865121. 10.3389\/fonc.2022.865121","journal-title":"Front Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-021-00784-1","article-title":"Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment","volume":"28","author":"Terrisse S","year":"2021","unstructured":"Terrisse S, Derosa L, Iebba V, et al.. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death Differ. 2021, 28:2778-96. 10.1038\/s41418-021-00784-1","journal-title":"Cell Death Differ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1659","article-title":"Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer","volume":"81","author":"Di Modica M","year":"2021","unstructured":"Di Modica M, Gargari G, Regondi V, et al.. Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer. Cancer Res. 2021, 81:2195-206. 10.1158\/0008-5472.CAN-20-1659","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01751-2","article-title":"The intestinal microbiome, weight, and metabolic changes in women treated by adjuvant chemotherapy for breast and gynecological malignancies","volume":"18","author":"Uzan-Yulzari A","year":"2020","unstructured":"Uzan-Yulzari A, Morr M, Tareef-Nabwani H, et al.. The intestinal microbiome, weight, and metabolic changes in women treated by adjuvant chemotherapy for breast and gynecological malignancies. BMC Med. 2020, 18:281. 10.1186\/s12916-020-01751-2","journal-title":"BMC Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93428-w","article-title":"Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis","volume":"11","author":"Zhang X","year":"2021","unstructured":"Zhang X, Yu L, Shi J, et al.. Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis. Sci Rep. 2021, 11:14024. 10.1038\/s41598-021-93428-w","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000562","article-title":"UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)","volume":"4","author":"Vaz-Luis I","year":"2019","unstructured":"Vaz-Luis I, Cottu P, Mesleard C, et al.. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open. 2019, 4:e000562. 10.1136\/esmoopen-2019-000562","journal-title":"ESMO Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/112367-gastrointestinal-microbiota-and-breast-cancer-chemotherapy-interactions-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:57Z","timestamp":1707508197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/112367-gastrointestinal-microbiota-and-breast-cancer-chemotherapy-interactions-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.31648","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,18]]}}}